Academic Journal
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).
| العنوان: | Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13). |
|---|---|
| المؤلفون: | Novak, U., Fehr, M., Schär, S., Dreyling, M., Schmidt, C., Derenzini, E., Zander, T., Hess, G., Mey, U., Ferrero, S., Mach, N., Boccomini, C., Böttcher, S., Voegeli, M., Cairoli, A., Ivanova, V.S., Menter, T., Dirnhofer, S., Scheibe, B., Gadient, S., Eckhardt, K., Zucca, E., Driessen, C., Renner, C. |
| المصدر: | EClinicalMedicine, vol. 64, pp. 102221 |
| سنة النشر: | 2023 |
| المجموعة: | Université de Lausanne (UNIL): Serval - Serveur académique lausannois |
| مصطلحات موضوعية: | Bortezomib, High risk biology, Ibrutinib, Mantle cell lymphoma |
| الوصف: | The Bruton's tyrosine kinase inhibitor ibrutinib and the proteasome inhibitor bortezomib have single-agent activity, non-overlapping toxicities, and regulatory approval in mantle cell lymphoma (MCL). In vitro, their combination provides synergistic cytotoxicity. In this investigator-initiated phase 1/2 trial, we established the recommended phase 2 dose of ibrutinib in combination with bortezomib, and assessed its efficacy in patients with relapsed or refractory MCL. In this phase 1/2 study open in 15 sites in Switzerland, Germany and Italy, patients with relapsed or refractory MCL after ≤2 lines of chemotherapy and both ibrutinib-naïve and bortezomib-naïve received six cycles of ibrutinibb and bortezomib, followed by ibrutinib maintenance. For the phase 1 study, a standard 3 + 3 dose escalation design was used to determine the recommended phase 2 dose of ibrutinib in combination with bortezomib. The primary endpoint in phase 1 was the dose limiting toxicities in cycle 1. The phase 2 study was an open-label, single-arm trial with a Simon's two-stage min-max design, with a primary endpoint of overall response rate (ORR) assessed by CT/MRI. This study was registered with ClinicalTrials.gov, NCT02356458. Between August 2015 and September 2016, nine patients were treated in the phase 1 study, and 49 patients were treated between November 2016 and March 2020 in the phase 2 of the trial. The ORR was 81.8% (90% CI 71.1, 89.8%, CR(u) 21.8%) which increased with continued ibrutinib (median 10.6 months) to 87.3%, (CR(u) 41.8%). 75.6% of patients had at least one high-risk feature (Ki-67 > 30%, blastoid or pleomorphic variant, p53 overexpression, TP53 mutations and/or deletions). In these patients, ibrutinib and bortezomib were also effective with an ORR of 74%, increasing to 82% during maintenance. With a median follow-up of 25.4 months, the median duration of response was 22.7, and the median PFS was 18.6 months. PFS reached 30.8 and 32.9 months for patients with a CR or Cru, respectively. The combination of ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/37781158; info:eu-repo/semantics/altIdentifier/eissn/2589-5370; info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_B8178ECC6BDA2; https://serval.unil.ch/notice/serval:BIB_B8178ECC6BDA; https://serval.unil.ch/resource/serval:BIB_B8178ECC6BDA.P001/REF.pdf |
| DOI: | 10.1016/j.eclinm.2023.102221 |
| الاتاحة: | https://serval.unil.ch/notice/serval:BIB_B8178ECC6BDA https://doi.org/10.1016/j.eclinm.2023.102221 https://serval.unil.ch/resource/serval:BIB_B8178ECC6BDA.P001/REF.pdf http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_B8178ECC6BDA2 |
| Rights: | info:eu-repo/semantics/openAccess ; CC BY-NC-ND 4.0 ; https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| رقم الانضمام: | edsbas.E7055A80 |
| قاعدة البيانات: | BASE |
| ResultId |
1 |
|---|---|
| Header |
edsbas BASE edsbas.E7055A80 961 3 Academic Journal academicJournal 960.976379394531 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.E7055A80&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://serval.unil.ch/notice/serval:BIB_B8178ECC6BDA# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Novak%2C+U%2E%22">Novak, U.</searchLink><br /><searchLink fieldCode="AR" term="%22Fehr%2C+M%2E%22">Fehr, M.</searchLink><br /><searchLink fieldCode="AR" term="%22Schär%2C+S%2E%22">Schär, S.</searchLink><br /><searchLink fieldCode="AR" term="%22Dreyling%2C+M%2E%22">Dreyling, M.</searchLink><br /><searchLink fieldCode="AR" term="%22Schmidt%2C+C%2E%22">Schmidt, C.</searchLink><br /><searchLink fieldCode="AR" term="%22Derenzini%2C+E%2E%22">Derenzini, E.</searchLink><br /><searchLink fieldCode="AR" term="%22Zander%2C+T%2E%22">Zander, T.</searchLink><br /><searchLink fieldCode="AR" term="%22Hess%2C+G%2E%22">Hess, G.</searchLink><br /><searchLink fieldCode="AR" term="%22Mey%2C+U%2E%22">Mey, U.</searchLink><br /><searchLink fieldCode="AR" term="%22Ferrero%2C+S%2E%22">Ferrero, S.</searchLink><br /><searchLink fieldCode="AR" term="%22Mach%2C+N%2E%22">Mach, N.</searchLink><br /><searchLink fieldCode="AR" term="%22Boccomini%2C+C%2E%22">Boccomini, C.</searchLink><br /><searchLink fieldCode="AR" term="%22Böttcher%2C+S%2E%22">Böttcher, S.</searchLink><br /><searchLink fieldCode="AR" term="%22Voegeli%2C+M%2E%22">Voegeli, M.</searchLink><br /><searchLink fieldCode="AR" term="%22Cairoli%2C+A%2E%22">Cairoli, A.</searchLink><br /><searchLink fieldCode="AR" term="%22Ivanova%2C+V%2ES%2E%22">Ivanova, V.S.</searchLink><br /><searchLink fieldCode="AR" term="%22Menter%2C+T%2E%22">Menter, T.</searchLink><br /><searchLink fieldCode="AR" term="%22Dirnhofer%2C+S%2E%22">Dirnhofer, S.</searchLink><br /><searchLink fieldCode="AR" term="%22Scheibe%2C+B%2E%22">Scheibe, B.</searchLink><br /><searchLink fieldCode="AR" term="%22Gadient%2C+S%2E%22">Gadient, S.</searchLink><br /><searchLink fieldCode="AR" term="%22Eckhardt%2C+K%2E%22">Eckhardt, K.</searchLink><br /><searchLink fieldCode="AR" term="%22Zucca%2C+E%2E%22">Zucca, E.</searchLink><br /><searchLink fieldCode="AR" term="%22Driessen%2C+C%2E%22">Driessen, C.</searchLink><br /><searchLink fieldCode="AR" term="%22Renner%2C+C%2E%22">Renner, C.</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => EClinicalMedicine, vol. 64, pp. 102221 ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2023 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => Université de Lausanne (UNIL): Serval - Serveur académique lausannois ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Bortezomib%22">Bortezomib</searchLink><br /><searchLink fieldCode="DE" term="%22High+risk+biology%22">High risk biology</searchLink><br /><searchLink fieldCode="DE" term="%22Ibrutinib%22">Ibrutinib</searchLink><br /><searchLink fieldCode="DE" term="%22Mantle+cell+lymphoma%22">Mantle cell lymphoma</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => The Bruton's tyrosine kinase inhibitor ibrutinib and the proteasome inhibitor bortezomib have single-agent activity, non-overlapping toxicities, and regulatory approval in mantle cell lymphoma (MCL). In vitro, their combination provides synergistic cytotoxicity. In this investigator-initiated phase 1/2 trial, we established the recommended phase 2 dose of ibrutinib in combination with bortezomib, and assessed its efficacy in patients with relapsed or refractory MCL. In this phase 1/2 study open in 15 sites in Switzerland, Germany and Italy, patients with relapsed or refractory MCL after ≤2 lines of chemotherapy and both ibrutinib-naïve and bortezomib-naïve received six cycles of ibrutinibb and bortezomib, followed by ibrutinib maintenance. For the phase 1 study, a standard 3 + 3 dose escalation design was used to determine the recommended phase 2 dose of ibrutinib in combination with bortezomib. The primary endpoint in phase 1 was the dose limiting toxicities in cycle 1. The phase 2 study was an open-label, single-arm trial with a Simon's two-stage min-max design, with a primary endpoint of overall response rate (ORR) assessed by CT/MRI. This study was registered with ClinicalTrials.gov, NCT02356458. Between August 2015 and September 2016, nine patients were treated in the phase 1 study, and 49 patients were treated between November 2016 and March 2020 in the phase 2 of the trial. The ORR was 81.8% (90% CI 71.1, 89.8%, CR(u) 21.8%) which increased with continued ibrutinib (median 10.6 months) to 87.3%, (CR(u) 41.8%). 75.6% of patients had at least one high-risk feature (Ki-67 > 30%, blastoid or pleomorphic variant, p53 overexpression, TP53 mutations and/or deletions). In these patients, ibrutinib and bortezomib were also effective with an ORR of 74%, increasing to 82% during maintenance. With a median follow-up of 25.4 months, the median duration of response was 22.7, and the median PFS was 18.6 months. PFS reached 30.8 and 32.9 months for patients with a CR or Cru, respectively. The combination of ... ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article in journal/newspaper ) Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => application/pdf ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => info:eu-repo/semantics/altIdentifier/pmid/37781158; info:eu-repo/semantics/altIdentifier/eissn/2589-5370; info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_B8178ECC6BDA2; https://serval.unil.ch/notice/serval:BIB_B8178ECC6BDA; https://serval.unil.ch/resource/serval:BIB_B8178ECC6BDA.P001/REF.pdf ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1016/j.eclinm.2023.102221 ) Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => https://serval.unil.ch/notice/serval:BIB_B8178ECC6BDA<br />https://doi.org/10.1016/j.eclinm.2023.102221<br />https://serval.unil.ch/resource/serval:BIB_B8178ECC6BDA.P001/REF.pdf<br />http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_B8178ECC6BDA2 ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => info:eu-repo/semantics/openAccess ; CC BY-NC-ND 4.0 ; https://creativecommons.org/licenses/by-nc-nd/4.0/ ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.E7055A80 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1016/j.eclinm.2023.102221
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Bortezomib
[Type] => general
)
[1] => Array
(
[SubjectFull] => High risk biology
[Type] => general
)
[2] => Array
(
[SubjectFull] => Ibrutinib
[Type] => general
)
[3] => Array
(
[SubjectFull] => Mantle cell lymphoma
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Novak, U.
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Fehr, M.
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Schär, S.
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Dreyling, M.
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Schmidt, C.
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Derenzini, E.
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Zander, T.
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hess, G.
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Mey, U.
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ferrero, S.
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Mach, N.
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Boccomini, C.
)
)
)
[12] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Böttcher, S.
)
)
)
[13] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Voegeli, M.
)
)
)
[14] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Cairoli, A.
)
)
)
[15] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ivanova, V.S.
)
)
)
[16] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Menter, T.
)
)
)
[17] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Dirnhofer, S.
)
)
)
[18] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Scheibe, B.
)
)
)
[19] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Gadient, S.
)
)
)
[20] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Eckhardt, K.
)
)
)
[21] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Zucca, E.
)
)
)
[22] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Driessen, C.
)
)
)
[23] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Renner, C.
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Type] => published
[Y] => 2023
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-locals
[Value] => edsbas
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsbas.oa
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => EClinicalMedicine, vol. 64, pp. 102221
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |